Finding New Treatments for Diabetes — How Many, How Fast . . . How Good?
Abstract
Two modern-day epidemics, HIV–AIDS and type 2 diabetes mellitus, have inspired impassioned calls for more effective interventions. In the 1980s, the rapid spread of HIV, with its associated severe, acute illness and high mortality, prompted activist groups and others to call for the accelerated approval of medications that showed promise of efficacy. There was no treatment available, and people were dying quickly. More recently, pressure to develop new drugs for type 2 diabetes has been stimulated by the remarkable worldwide increase in the incidence of this disease (54% in the past 7 years in the United States1) and the . . .
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The increased number of choices available to practitioners and patients has heightened uncertainty regarding the most appropriate means of treating type 2 diabetes.
“the increased number of choices available to practitioners and patients has heightened uncertainty regarding the most appropriate means of treating this widespread disease (14)”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [14]
The citation lists haven’t been fetched yet
References 4 · Cited by 216
- Authors
- Nathan, D. M.
- Affiliations
- Harvard University (US)
- Corresponding author
- Nathan, David M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-02
- Volume
- 356
- Issue
- 5
- Pages
- 437-440
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2005038357
- Cited by
- 216
- References
- 4
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 5 · 2019: 7 · 2018: 6 · 2017: 7 · 2016: 7 · 2015: 8 · 2014: 3 · 2013: 13 · 2012: 8
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- type 2 diabetes, drug development, new treatments, accelerated approval, HIV/AIDS, incidence trends, antidiabetic drugs
- MeSH terms
- Sitagliptin Phosphate, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Glycoproteins, Humans, Hypoglycemic Agents, Peptide Fragments, Pyrazines, Triazoles, United States, United States Food and Drug Administration, Drug Approval, Dipeptidyl Peptidase 4, History, 20th Century, History, 21st Century, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors, Adenosine Deaminase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
